Protective effects of lactoferrin in Escherichia coli-induced bacteremia in mice:: Relationship to reduced serum TNF alpha level and increased turnover of neutrophils

被引:36
作者
Zimecki, M
Artym, J
Chodaczek, G
Kocieba, M
Kruzel, ML
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA
[2] Polish Acad Sci, Inst Immunol & Expt Therapy, Dept Expt Therapy, PL-53114 Wroclaw, Poland
关键词
bacteremia; lactoferrin; TNF alpha; neutrophils;
D O I
10.1007/s00011-004-1257-1
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objective and Design:Previous studies demonstrated that lactoferrin (LF), given intravenously (i.v.), 24 h before lethal Escherichia coli (E. coli) infection, protects mice against mortality. The aim of this investigation was to determine whether downregulation of serum TNF alpha activity and increase of neutrophil number in the circulation and bone marrow by LF could contribute to the protective action of LF against E. coli-induced sepsis. Materials and subjects:CBA female mice, 10-12 week old, weight 20-22 g, were used. Treatment:Mice were given 10 mg LF i.v. either 2 h or 24 h before i.v. administration of lethal dose of E. coli (5 x 10(8)). Methods:Serum activities of TNF alpha and IL-1 were determined by bioassays 2 h following E. coli or LF injection. The blood and bone marrow smears were stained with Giemsa and May-Grunwald reagents and reviewed histologically. Results:LF given 24 h before E. coli caused a 60% reduction of TNF alpha released into circulation. However, pretreatment of mice with LF 2 h before bacterial challenge resulted in strong (15 fold) increase of TNF alpha serum level. Analysis of bone marrow cell composition revealed a significant increase in neutrophil lineage cell content (myelocytes, bands and mature neutrophils) following 24 h pretreatment with LF (51.8% of the total cell count), versus PBS control (32.7%) and 2 h LF pretreatment (35.8%). The percentage of neutrophils (bands and mature forms) in the peripheral blood rose to 47.4% versus 32% and 32%, respectively. Intravenous administration of LF increased also interleukin 1 (IL-1) concentration in the circulation of noninfected mice. Conclusions:This investigation has added more information regarding the mechanism of the protective action of LF in E. coli-induced bacteremia by revealing the phenomenon of accelerated neutrophil recruitment and down-regulation of E. coli-induced TNF alpha serum level.
引用
收藏
页码:292 / 296
页数:5
相关论文
共 45 条
  • [11] Lactoferrin-lipopolysaccharide interaction: Involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide
    ElassRochard, E
    Roseanu, A
    Legrand, D
    Trif, M
    Salmon, V
    Motas, C
    Montreuil, J
    Spik, G
    [J]. BIOCHEMICAL JOURNAL, 1995, 312 : 839 - 845
  • [12] ELLISON RT, 1994, ADV EXP MED BIOL, V357, P71
  • [13] A HIGHLY SENSITIVE CELL-LINE, WEHI-164 CLONE 13, FOR MEASURING CYTOTOXIC FACTOR TUMOR-NECROSIS-FACTOR FROM HUMAN-MONOCYTES
    ESPEVIK, T
    NISSENMEYER, J
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1986, 95 (01) : 99 - 105
  • [14] Gregory SH, 1996, J IMMUNOL, V157, P2514
  • [15] Complementary adhesion molecules promote neutrophil-Kupffer cell interaction and the elimination of bacteria taken up by the liver
    Gregory, SH
    Cousens, LP
    van Rooijen, N
    Döpp, EA
    Carlos, TM
    Wing, EJ
    [J]. JOURNAL OF IMMUNOLOGY, 2002, 168 (01) : 308 - 315
  • [16] HAVELL EA, 1989, J IMMUNOL, V143, P2894
  • [17] Hazinski M F, 1993, Am J Crit Care, V2, P224
  • [18] Perioperative anti-endotoxin strategies
    Houdijk, APJ
    Meijer, C
    Cuesta, MA
    Meyer, S
    VanLeeuwen, PAM
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 : 93 - 97
  • [19] ISOLATION AND PARTIAL CHARACTERIZATION OF A LACTOTRANSFERRIN RECEPTOR FROM MOUSE INTESTINAL BRUSH-BORDER
    HU, WL
    MAZURIER, J
    MONTREUIL, J
    SPIK, G
    [J]. BIOCHEMISTRY, 1990, 29 (02) : 535 - 541
  • [20] Immunomodulatory therapies in sepsis
    Kox, WJ
    Volk, T
    Kox, SN
    Volk, HD
    [J]. INTENSIVE CARE MEDICINE, 2000, 26 (Suppl 1) : S124 - S128